Coverart for item
The Resource Targeted therapies in breast cancer, Harold J. Burstein, (electronic resource)

Targeted therapies in breast cancer, Harold J. Burstein, (electronic resource)

Label
Targeted therapies in breast cancer
Title
Targeted therapies in breast cancer
Statement of responsibility
Harold J. Burstein
Creator
Subject
Genre
Language
eng
Summary
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th
Member of
http://library.link/vocab/creatorName
Burstein, Harold J
Dewey number
616.99449061
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
  • handbooks
Series statement
Oxford American pocket notes
http://library.link/vocab/subjectName
  • Breast
  • Drug targeting
Label
Targeted therapies in breast cancer, Harold J. Burstein, (electronic resource)
Instantiates
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Color
multicolored
Contents
Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References
Control code
ocn795706882
Dimensions
unknown
Extent
1 online resource (54 pages)
File format
unknown
Form of item
online
Isbn
9780199749751
Level of compression
unknown
Note
eBooks on EBSCOhost
Other physical details
illustrations
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)795706882
Label
Targeted therapies in breast cancer, Harold J. Burstein, (electronic resource)
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Color
multicolored
Contents
Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References
Control code
ocn795706882
Dimensions
unknown
Extent
1 online resource (54 pages)
File format
unknown
Form of item
online
Isbn
9780199749751
Level of compression
unknown
Note
eBooks on EBSCOhost
Other physical details
illustrations
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)795706882

Library Locations

    • InternetBorrow it
      Albany, Auckland, 0632, NZ
Processing Feedback ...